Hämato-Onkologie im Medicum
- Address
- Schwachhauser Heerstraße 50, 28209 Bremen, Germany
Hämato-Onkologie im Medicum - Breast Cancer Research Center
Hämato-Onkologie im Medicum is a specialized hematology-oncology research center dedicated to advancing targeted therapies for cancer patients. The center demonstrates particular expertise in precision medicine approaches for breast cancer, focusing on genetic testing and personalized treatment strategies for high-risk patient populations.
- Germline BRCA mutation-positive breast cancer research
- HER2-negative primary breast cancer treatment optimization
- PARP inhibitor therapy in adjuvant settings
The center is actively investigating olaparib as an adjuvant treatment option for patients with germline BRCA mutations and high-risk breast cancer characteristics. Their research emphasizes improving invasive disease-free survival outcomes through innovative therapeutic interventions targeting specific genetic vulnerabilities in breast cancer. This work represents a commitment to translating genomic insights into meaningful clinical benefits for patients with hereditary cancer predisposition.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 37 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hämato-Onkologie im Medicum
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS | Institut fuer Frauengesundheit GmbH | Phase III | Recruiting | Oct 2022 | — |
IMP list
lock Showing 1 of 37 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2018-06-13 | 2025-11-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.